The global pharmaceutical sterility testing market size is anticipated to reach USD 3.28 billion by 2030 and is projected to grow at a CAGR of 11.02% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing number of drug launches worldwide, and rising government investments are anticipated to influence the global market positively. As pharmaceutical companies are introducing an array of new drugs to the market, there is a parallel surge in the demand for rigorous sterility testing protocols. Besides, stringent regulatory requirements for pharmaceuticals products further support market growth. Thus, an upsurge in novel drug launches provided unprecedented growth opportunities to the pharmaceutical sterility testing market.
In addition, increasing emphasis on R&D activities in the pharmaceutical industry profoundly impacts the pharmaceutical sterility testing market. As pharmaceutical companies are proactively involved in the discovery and development of innovative & advanced drug formulations, there is a growing need for robust sterility testing protocols to ensure the safety and efficacy of these products. R&D activities drive the development of new pharmaceuticals, biologics, and vaccines, necessitating comprehensive sterility testing methodologies to comply with regulatory requirements.
Furthermore, stringent regulations by regulatory bodies for pharmaceutical product approval prompt pharmaceutical companies to invest significantly in R&D to meet these evolving standards. As a result, the market experiences a surge in demand for state-of-the-art testing solutions to align with the regulatory landscape. For instance, in September 2023, Sartorius AG introduced a sterisart septum for sampling from a sterility testing unit. It is a closed system for testing based on the membrane filtration method that mitigates the risk of secondary contamination. Such service launches offered a competitive edge in the market.
Moreover, the pharmaceutical industry's commitment to addressing unmet medical needs and discovering innovative therapeutic avenues further amplifies the importance of robust sterility testing protocols. The need for accuracy & reliability in detecting any potential contaminants becomes paramount to ensure the safety and efficacy of these newly launched drugs.
Request a free sample copy or view report summary: Pharmaceutical Sterility Testing Market Report
Based on type, the outsourcing segment led the market with the largest revenue share of 59.25% in 2023. The segment growth is driven by increasing requirements for Outsourcing sterility testing as attractive alternative for several small- & medium-sized pharmaceutical and medical device companies, which may lack the infrastructure to conduct quality sterility testing
Based on product type, the kits and reagents segment held the market with the largest revenue share of 60.30% in 2023, attributing to a standardized and reliable techniques to determine the absence of live microorganisms in pharmaceutical products
Based on test type, the bioburden testing segment led the market with the largest revenue share of 41.71% in 2023. The segment is driven by strict quality control processes and the demand for testing to quantify microbial contamination of a product at different stages of production from initial manufacturing to final distribution
Based on sample, the pharmaceuticals segment led the market with the largest revenue share of 42.45% in 2023. The products are widely used dosage forms. The growing demand or these dosage forms globally is one of the major factors driving this segment
Based on end-use, the pharmaceutical companies dominated the market in 2023. These companies conduct sterility tests to ensure the safety of the products, especially oral dosage forms, as most of these products are ingested by patients
North America dominated the market with a revenue share of 49.45% in 2023. The presence of a large number of major market players in this region is expected to contribute to the market growth significantly. Stringent regulatory requirements for sterility testing of pharmaceuticals and medical devices in this region further supports market growth
Grand View Research has segmented the global pharmaceutical sterility testing market based on type, product type, test type, sample, end-use, and region:
Pharmaceutical Sterility Testing Type Outlook (Revenue, USD Million, 2018 - 2030)
In-House
Outsourcing
Pharmaceutical Sterility Testing Product Type Outlook (Revenue, USD Million, 2018 - 2030)
Kits & Reagents
Instruments
Services
Pharmaceutical Sterility Testing Test Type Outlook (Revenue, USD Million, 2018 - 2030)
Sterility Testing
Membrane Filtration
Direct Inoculation
Product Flush
Bioburden Testing
Bacterial Endotoxin Testing
Rapid Microbial Method
ATP Bioluminescence
Fluorescent -Based
Solid-phase Cytometry
Others
Pharmaceutical Sterility Testing Sample Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceuticals
Medical Devices
Biopharmaceuticals
Pharmaceutical Sterility Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)
Compounding Pharmacies
Medical Device Companies
Pharmaceutical Companies
Others
Pharmaceutical Sterility Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Netherlands
Switzerland
Sweden
Belgium
Russia
Asia Pacific
Japan
China
India
Australia
South Korea
Philippines
Malaysia
New Zealand
Singapore
Thailand
Latin America
Brazil
Mexico
Argentina
Colombia
Chile
Middle East and Africa (MEA)
South Africa
Saudi Arabia
Egypt
Israel
UAE
List of Key Players in Pharmaceutical Sterility Testing Market
SGS SA
Pacific Biolabs
Steris Plc
Boston Analytical
Sotera Health Company (Nelson Labs)
Sartorius Ag
Solvias Ag
SGS SA
Labcorp
Pace Analytical
Charles River Laboratories
Thermo Fisher Scientific, Inc.
Rapid Micro Biosystems, Inc.
Almac Group
Labor LS SE & Co. KG
"The quality of research they have done for us has been excellent..."